TRVI - Trevi Therapeutics initiated at outperform at Oppenheimer on chronic cough candidate

Oppenheimer has begun Trevi Therapeutics (NASDAQ:TRVI) with an overweight rating citing the potential of its candidate Haduvio (nalbuphine ER) specifically for chronic cough associated with idiopathic pulmonary fibrosis. Haduvio is in phase 2 for that indication. It is also in phase 2 for chronic kidney disease and phase 3 for prurigo nodularis, a rare, itchy skin disease. Phase 2 data for the chronic cough indication is expected in Q3. Phase 3 data for prurigo nodularis is expected this quarter. The firm has a $10 target price (~355% upside based on Tuesday's close). Analyst Leland Gershell said he sees at least $750M in peak sales for Haduvio. Seeking Alpha's Quant Rating views Trevi (TRVI) as a hold.

For further details see:

Trevi Therapeutics initiated at outperform at Oppenheimer on chronic cough candidate